retatrutide phase 2 trial Michael Weintraub, MD on X: "Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% weight loss in half of people with #obesity. This amount of weight Phase 2 Trial of Retatrutide

Friedman RA, Van Laer L, Huentelman MJ, Sheth SS, Van Eyken E, Corneveaux JJ, Tembe WD, Halperin RF, Thorburn AQ, Thys S, Bonneux S, Fransen E, Huyghe J, Pyykko I, Cremers CW, Kremer H, Dhooge I, Stephens D, Orzan E, Pfister M, Bille M, Parving A, Sorri M, Van de Heyning PH, Makmura L, Ohmen JD, Linthicum FH Jr, Fayad JN, Pearson JV, Craig DW, Stephan DA, Van Camp G

We are committed to this level of transparency, providing clean, science-forward formulations that you can trust

Only a small fraction of people who meet eligibility criteria ever receive it

As such, many researchers are curious about ipamorelin benefits

If you have any questions, please email our support team at [email protected] or call us toll-free at 1-888-862-1210.